Question 1

Has Enrique Pelayo received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $5,369,020 in general payments to Enrique Pelayo across 716 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Enrique Pelayo did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Enrique Pelayo come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Merck	200	$2,857,872
GSK	270	$1,207,652
Acella Pharmaceuticals, LLC	3	$341,115
Astrazeneca UK Limited	1	$243,219
Ionis Pharmaceuticals, Inc.	15	$232,455
AbbVie	138	$226,130
Sanofi Pasteur Inc.	4	$80,558
Chiesi USA, Inc.	10	$41,718
Avion Pharmaceuticals	2	$39,835
Kowa Research Institute, Inc.	26	$36,336
Mitsubishi Tanabe Pharma Development America, Inc.	4	$31,747
Eisai Inc.	23	$29,819
Amarin Pharma, Inc.	7	$245
Lilly USA, LLC	8	$149
Revance Therapeutics, Inc.	2	$96
Bayer	2	$49
Novo Nordisk	1	$24

Enrique Pelayo

Payments from drug & device makers

Who reported the general payments

How this compares

Other internal medicine in Miami